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Progressive multi-focal leucoencephalopathy and progressive multi-focal leucoencephalopathy-immune reconstitution inflamma-
tory syndrome are caused by infection of the central nervous system with the JC polyoma virus. Both are complications of
monoclonal antibody therapy in multiple sclerosis and other autoimmune diseases. Progressive multi-focal leucoencephalopa-
thy-immune reconstitution inflammatory syndrome can obscure the diagnosis of progressive multi-focal leucoencephalopathy
and lead to severe clinical disability and possibly death. Different from progressive multi-focal leucoencephalopathy, in which
demyelination results from oligodendrocyte lysis by JC virus in the absence of an immune response, tissue destruction in
progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome is caused by a vigorous immune
response within the brain. The cells and mediators that are involved in progressive multi-focal leucoencephalopathy-immune
reconstitution inflammatory syndrome are as yet poorly understood. We examined two patients with multiple sclerosis, who
developed progressive multi-focal leucoencephalopathy and later progressive multi-focal leucoencephalopathy-immune recon-
stitution inflammatory syndrome under natalizumab therapy. Due to initially negative JC viral deoxyribonucleic acid testing in
the cerebrospinal fluid, a diagnostic brain biopsy was performed in one patient. Histopathology revealed brain inflammation
characterized by a prominent T cell infiltrate (CD4+4CD8+ T cells), but also B/plasma cells and monocytes. Despite very low
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JC viral load, both patients showed high intrathecal anti-JC virus antibodies. Brain-infiltrating CD4+ T cells were studied
regarding antigen specificity and function. CD4+ T cells were highly specific for peptides from several JC virus proteins,
particularly the major capsid protein VP1. T cell phenotyping revealed CD4+ Th1 and bifunctional Th1-2 cells. The latter secrete
large amounts of interferon- and interleukin-4 explaining the strong brain inflammation, presence of plasma cells and secretion
of intrathecal anti-VP1 antibodies. The functional phenotype of brain-infiltrating JC virus-specific CD4+ T cells was confirmed
and extended by examining brain-derived JC virus-specific CD4+ T cell clones. Our data provide novel insight into the patho-
genesis of progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome and indicate that JC
virus-specific CD4+ T cells play an important role in both eliminating JC virus from the brain, but also in causing the massive
inflammation with often fatal outcome.
Keywords: PML; PML-IRIS; CD4 + T cells; JC polyoma virus; immunopathogenesis
Abbreviations: IRIS = immune reconstitution inflammatory syndrome; JC virus = John Cunningham virus; PML = progressive
multi-focal leucoencephalopathy; VLP = virus-like particles
Introduction
Progressive multi-focal leucoencephalopathy (PML) was first
described by Astrom et al. (1958). Crystalline inclusions in oligo-
dendrocytes indicated a viral infection (Zurhein and Chou, 1965),
and the polyoma John Cunningham (JC) virus was identified as the
causative agent (Padgett et al., 1971). PML is an opportunistic
infection that occurs in states of acquired or hereditary immuno-
compromise such as HIV infection, or rarely during autoimmune
diseases (Major, 2010). Infection with JC virus is highly prevalent
in healthy adults, and 560% of the population carries a latent/
persistent infection (Egli et al., 2009). Recently, PML has emerged
as a serious adverse event in monoclonal antibody therapy of
autoimmune diseases, in particular patients with multiple sclerosis
treated with natalizumab (anti-VLA-4) (Kleinschmidt-DeMasters
and Tyler, 2005; Langer-Gould et al., 2005; Anonymous, 2010;
Jilek et al., 2010). Other monoclonal antibodes such as rituximab
(anti-CD20), infliximab [anti-tumour necrosis factor (TNF)-] and
the IgG1-TNF receptor 2 fusion protein etanercept that are used
to treat rheumatoid arthritis have also been associated with PML
(Major, 2010). Efalizumab (anti-leucocyte function-associated
antigen-1) has been withdrawn from the market (Pugashetti and
Koo, 2009). With more than 100 cases with PML reported in
patients with multiple sclerosis receiving natalizumab, the PML
incidence is between 1:500 and 1:1000 and jeopardizes the use
of this highly effective treatment (Anonymous, 2010).
The pathogenesis of PML is characterized by a lytic infection of
oligodendrocytes and abortive infection of astrocytes in the ab-
sence of a notable immune reaction (Koralnik, 2006; Major,
2010). Although the mechanisms of controlling JC virus infection
are as yet incompletely understood, both humoral and/or cellular
immune responses probably play a role (Weber et al., 1997; Du
Pasquier et al., 2001, 2004a; Khanna et al., 2009). Accordingly,
the presence of JC virus-specific CD8 + cytotoxic T cells has been
linked to the recovery from PML, while these cells were absent in
cases with PML with fatal outcome (Koralnik et al., 2002; Du
Pasquier et al., 2004a, 2006). The observations that PML occurs
preferentially in situations of decreased CD4 + T cell numbers or
compromised CD4 + cell functions such as AIDS and idiopathic
CD4 + lymphopenia (Stoner et al., 1986; Gillespie et al., 1991;
Zonios et al., 2008) and often resolves following restoration of
CD4 + numbers, indicate that both CD4 + and CD8 + JC
virus-specific T cells are important for host protection.
Different from the general immunosuppresion, in AIDS, mono-
clonal antibody-based therapies inhibit specific immune functions
such as cell migration across the blood–brain barrier during nata-
lizumab therapy, or eliminate certain immune cells such as
CD20-expressing B cells in the case of rituximab (Lutterotti and
Martin, 2008). With respect to anti-VLA-4 therapy, it is assumed
that PML results from compromised immune surveillance of the
CNS, since activated T cells and CD209 + dendritic cells cannot
cross the blood–brain barrier (Yednock et al., 1992; Stuve et al.,
2006; Del Pilar Martin et al., 2008), thus compromising local anti-
gen presentation in the CNS (Del Pilar Martin et al., 2008).
Alternatively, inhibition of VLA-4/vascular cell adhesion
molecule-1 (VCAM-1) interactions, which serve as a retention
signal for haematopoietic precursor cells in the bone marrow,
may lead to release of JC virus from its natural niches (Tan
et al., 2009a), increased viral replication and occurrence of JC
virus variants with tropism for CNS cells (Houff et al., 1988;
Ransohoff, 2005). Cessation of monoclonal antibody therapy in
PML re-establishes immune surveillance for JC virus-infected cells
in the CNS and leads to clinically apparent inflammatory responses
in the brain. Inflammation can be visualized by contrast-enhancing
lesions on MRI due to opening of the blood–brain barrier. The
latter manifestation of PML has been termed PML-immune recon-
stitution inflammatory syndrome (IRIS) (Koralnik, 2006; Tan et al.,
2009b). PML-IRIS can lead to rapid deterioration of the patient’s
clinical state and death in 30–50% of cases (Tan et al., 2009b).
Its cellular and molecular pathogenesis, i.e. which T cell subtypes,
antibodies or cytokines are involved, are currently poorly under-
stood. Diagnosing PML and PML-IRIS as early as possible and
identifying effective therapies based on the underlying disease
mechanisms are important goals not only in multiple sclerosis,
but also in a number of other autoimmune diseases, during
acquired immunodeficiencies, during malignancies and in trans-
plant medicine.
In the present study, we characterized in detail the brain tissue
infiltrate with respect to cellular composition as well as the
humoral anti-JC virus-specific immune response in the CSF.
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Furthermore, we established from a brain biopsy ex vivo bulk
T cell cultures and CD4 + T cell clones, which we then studied
regarding antigen specificity, functional phenotype, relative abun-
dance and T cell receptor expression. This is the first study that
investigates the antigen specificity and phenotype of brain-
infiltrating T cells in PML-IRIS.
Materials and methods
Patients
Patients with multiple sclerosis developing PML and
PML-IRIS under natalizumab therapy
Clinical, neuroimaging (MRI), virological and clinical chemistry findings
are summarized in Supplementary Table 1 and Fig. 1 (Patient 1);
Supplementary Table 2 and Fig. 2 (Patient 2).
HLA-class II types: DRB1*13:01, DRB1*16:01; DRB3*02:02;
DRB5*02:02; DQA1*01:02, DQA1*01:03; DQB1*05:02, DQB1*
06:03 (Patient 1); and DRB1*11:03, DRB1*15:01; DRB3*02:02;
DRB5*01:01; DQA1*01:02, DQA1*05:XX (X indicating not typed to
the exact subtype); DQB1*03:01, DQB1*06:02 (Patient 2).
Other patients with PML, PML-IRIS and inflammatory
neurological controls
Brain biopsy tissue from a 48-year-old male with AIDS-related PML
and subsequent PML-IRIS, and CSF cells from two patients with PML
based on hereditary immunodeficiencies, i.e. a 63-year-old male with
idiopathic CD4 + lymphopenia and a 20-year-old male with hyper-IgE
syndrome, were examined. Furthermore, CSF cells from a 50-year-old
male suffering from neurosyphilis and a 32-year-old female with relap-
sing–remitting multiple sclerosis were examined (for clinical case sum-
maries see Supplementary material).
Neuropathology
Small tissue fragments of a total volume of 0.1 ml were obtained by
open biopsy. Following fixation in buffered formalin for 2 h, tissue was
embedded in paraffin. Microtome sections of 4 mm were stained with
haematoxylin and eosin, van Gieson’s trichrome, periodic acid-Schiff,
Turnbull’s stain for siderin and Luxol. Immunohistochemical staining
was performed on an automated Ventana HX immunohistochemistry
system, benchmark (Ventana-Roche Medical Systems) following the
manufacturer’s instructions using the following antibodies: anti-
CD45/LCA (Dako; M701), anti-CD3 (Dako; M1580), anti-CD45R0
(Dako; M0742), anti-CD20 (Dako; M0755), anti-CD79a (Dako;
M7050), anti-CD68 (Immunotech/Beckmann-Coulter), anti-HLA-DR
(Dako; M775), anti-NF (Zymed/Invitrogen; 80742971), anti-GFAP
(Dako; Z334) and anti-p53 (Dako; M7001).
Brain tissue processing and expansion
of brain-, cerebrospinal
fluid- and peripheral blood-derived
mononuclear cells
A biopsy of 0.033 ml was cut into small pieces and disrupted by
incubation in a solution containing 1 mg/ml collagenase A (Roche
Diagnostics) and 0.1 mg/ml DNAse I (Roche) at 37C in a water
bath for 45 min. The resulting cell suspension was washed three
times, and brain-derived mononuclear cells were separated using a
Percoll density gradient centrifugation (GE Healthcare). Cells were re-
suspended in a 30% Percoll solution and carefully underlayered with a
78% Percoll solution. After centrifugation brain-derived mononuclear
cells were gathered from the interface of the gradient. Brain tissue
from the patient with AIDS PML-IRIS was processed in a similar way.
CSF-derived mononuclear cells were obtained directly from a diag-
nostic spinal tap, and peripheral blood mononuclear cells separated by
Ficoll density gradient centrifugation (PAA).
Brain, CSF and peripheral blood-derived mononuclear cells were ex-
panded in 96-well U-bottom microtitre plates by seeding 2000 cells
per well together with 2  105 non-autologous, irradiated peripheral
blood mononuclear cells (3000 rad) and 1 mg/ml of phytohaemagglu-
tinin-L (Sigma). Medium consisted of Roswell Park Memorial Institute
(RPMI) (PAA) containing 100 U/ml penicillin/streptomycin (PAA),
50 mg/ml gentamicin (BioWhittaker, Cambrex), 2 mM L-glutamine
(GIBCO, Invitrogen) and 5% heat-decomplemented human serum
(PAA). After 24 h, 20 U/ml of human recombinant IL-2 (hrIL-2,
Tecin, Roche Diagnostics) were added and additional hrIL2 was
added every 3–4 days. After 2 weeks, cells were pooled and analysed,
cryopreserved or restimulated with 1 mg/ml phytohaemagglutinin,
20 U/ml hrIL-2 and allogeneic irradiated peripheral blood mononuclear
cells.
Flow cytometry analysis of
brain-derived mononuclear cells
Brain-derived mononuclear cells directly from brain digestion were
stained with the following antibodies for surface markers: CD45
(AmCyan, 2D1, BD Pharmingen), CD56 (Alexa 488, B159, BD
Pharmingen), CD3 (PeCy7, UCHT1, eBioscience), CD4 (APC, RPA-T4,
eBioscience), CD8 (PB, DK25, Dako), CD45RO (FITC, UCHL1,
eBioscience), CD19 (FITC, HIB19, BD Pharmingen), CD38 (APC, HIT2,
BD Pharmingen) and CD27 (APC-Alexa 750, CLB-27/1, Invitrogen).
Analysis was performed on a LSRII (BD Biosciences) flow cytometer.
Proteins and peptides
For the identification of JC virus-specific T cells, 204 (13–16-mer) pep-
tides covering the entire JC viral proteome, were applied. Peptides
were synthesized and provided by Peptides and Elephants GmbH.
These 204 peptides overlap by five amino acids and include 35
common single amino acid mutations (Supplementary Table 3). To
account for amino acid variations that occur among the different JC
virus genotypes and strains, amino acid sequences of each JC virus
encoded protein including Agno, VP1, VP2, VP3, large T antigen and
small T antigen, from all 479 JC virus genomic sequences available in
GenBank (by March 2008), were aligned and those polymorphisms,
which were prevalent in 41% of the all retrieved sequences, were
defined as common mutations.
In order to determine which individual peptides are recognized by
CNS-derived T cells, a 2D seeding scheme was applied. Peptides were
arranged in a set of 82 pools and each pool contained five different
peptides (Supplementary Table 4). By the combination of different
peptides in each well according to a rectangular matrix and each in-
dividual peptide appearing in exactly two pools, in which the residual
peptides differed, immunogenic candidate peptides could be identified
at the intersections of the positive pools.
JC virus VP1 protein forms virus-like particles (VLP), and VP1 and
VLP are therefore used as interchangeable terms. VP1 protein forming
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VLP (VP1/VLP) was generated by the Life Science Incubator, as pre-
viously described (Goldmann et al., 1999).
Twenty-mer myelin peptides with an overlap of 10 amino acids and
covering myelin basic protein (16 peptides), myelin oligodendrocyte
glycoprotein (25 peptides) and proteolipid protein (27 peptides) were
synthesized and provided by PEPScreen, Custom Peptide Libraries,
SIGMA (Supplementary Table 5). Tetanus toxoid (Novartis Behring)
was used as positive control.
Proliferative assays
Recognition of JC virus peptides, VP1/VLP and tetanus toxoid were
tested by seeding duplicates in 96-well U-bottom microtitre plates
2–2.5  104 brain-, CSF- or peripheral blood-derived phytohaemagglu-
tinin-expanded cells per well and 1  105 autologous irradiated periph-
eral blood mononuclear cells with or without peptides for 72 h.
Unmanipulated peripheral blood mononuclear cells were tested at
2  105 cells/well in a 7-day primary proliferation. In addition to tetanus
toxoid, phytohaemagglutinin-L stimulation was added as positive con-
trol. All JC virus peptides were either tested in pools or as individual
peptides at a final concentration of 2 mM per peptide for peptides in
pools and at a concentration of 10 mM for individual peptides. VP1/
VLP was tested at 2 mg/ml, tetanus toxoid at 5 mg/ml and phytohaem-
agglutinin at 1 mg/ml. Proliferation was measured by 3H-thymidine
(Hartmann Analytic) incorporation in a scintillation beta counter
(Wallac 1450, PerkinElmer). The stimulatory index was calculated as:
Stimulatory index ¼Mean counts per minute (peptide)/
Mean counts per minute (background)
Responses were considered as positive when the stimulatory index
43, counts per minute 41000 and at least three standard deviations
(SDs) above average background counts per minute. Myelin peptides
were tested as individual peptides at 5 mM, as described above.
Generation of brain-derived
VP1/VLP-specific T cell clones
Brain-derived phytohaemagglutinin-expanded cells (2.5  104) were
seeded in 96-well U-bottom microtitre plates with 1  105 autologous
irradiated peripheral blood mononuclear cells with or without VP1/VLP
protein. After 48 h of culture, plates were split into mother and daugh-
ter plates. Proliferation was measured in daughter plates by
methyl-3H-thymidine incorporation. VP1/VLP-responsive cultures
were identified in mother plates, and IL-2 was added every 3–4
days until Day 12. T cell clones were established from positive cultures
by seeding cells from VP1/VLP-responsive wells under limiting dilution
conditions at 0.3 and 1 cell/well in 96-well U-bottom microtitre plates,
and addition of 2  105 allogeneic, irradiated peripheral blood mono-
nuclear cells and 1 mg/ml of phytohaemagglutinin-L in complete RPMI.
After 24 h, 20 U/ml of human recombinant IL-2 was added. VP1/VLP
specificity was then confirmed by seeding 2.5  104 cells from grow-
ing colonies with autologous irradiated peripheral blood mononuclear
cells with or without VP1/VLP protein for 72 h. Specific cultures were
restimulated every 2 weeks with 1 mg/ml phytohaemagglutinin-L,
20 U/ml hrIL-2 and allogeneic irradiated peripheral blood mononuclear
cells and hrIL2 was added every 3–4 days.
T cell receptor analysis
T cell receptor Vb chain expression was assessed in
phytohaemagglutinin-expanded cells and T cell clones by 22
anti-TCRBV monoclonal antibodies (Immunotech) (Muraro et al.,
2000) in combination with CD4 (APC, eBioscience) and CD8 (PB,
PB, DakoCytomation).
Determination of precursor frequency
in central nervous system-derived
mononuclear cells
Frequencies of VP1/VLP-specific cells were determined by limiting
dilution. Twenty, 200, 2000 or 20 000 brain-derived phytohaemagglu-
tinin-expanded cells were seeded in quadruplicates in 96-well
U-bottom microtitre plates with 1  105 autologous-irradiated periph-
eral blood mononuclear cells with or without VP1/VLP protein. After
72 h, proliferation was measured by methyl-3H-thymidine incorpor-
ation. Frequencies were calculated as previously described (Taswell,
1981). Observed data included: r, the number of negatively respond-
ing cultures or wells of each dose i; n, the total number of wells per
dose i and  the number of cells in the dose i. Calculated data
were pi = ri/ni, the fraction of negatively responding cultures of each
dose i. The frequency was calculated using the following formula:
f = (ln pi)/i.
Cytokine production
For intracellular cytokine staining, phytohaemagglutinin-expanded cells
and T cell clones were analysed 12 days after last restimulation. Cells
were stimulated with phorbol myristate acetate (50 ng/ml, Sigma) and
ionomycin (1mg/ml, Sigma) in the presence of Brefeldin A (10 mg/ml,
eBioscience) for 5 h. Cells were then stained with LIVE/DEAD Fixable
Dead Cell Stain Kit (AmCyan, Molecular Probes, Invitrogen), fixed and
permeabilized with the corresponding buffers (eBioscience) and stained
for CD3 (PE, DakoCytomation), CD8 (PB, DakoCytomation), IFN-
(FITC, BDPharmingen), IL-4 (PE-Cy7, eBioscience) and IL-17 A (Alexa
Fluor-647, eBioscience) at room temperature. IFN--, IL-4- and IL-2
levels were also determined by ELISA following the manufacturer’s
protocol (Biosource) in culture supernatants of
phytohaemagglutinin-expanded cells and in T cell clones 72 h after
stimulation with phytohaemagglutinin or VP1/VLP.
Quantification of messenger RNA
expression levels by real
time-polymerase chain reaction
For messenger RNA gene expression assays, the primer and probe sets
(Tbet, Hs00203436_m1 and Gata3, Hs00231122_m1) were purchased
from Applied Biosystems. Ribosomal RNA (18S) was used as endogen-
ous control, and the relative gene expression was calculated by the
Ct method using brain-derived phytohaemagglutinin-expanded
cells as calibrator.
Enzyme-linked immunosorbent assay
for VP1/VLP-specific antibodies
The titre of VP1/VPL-specific immunoglobulin G antibodies in CSF and
sera from both patients with PML-IRIS was determined as previously
described (Weber et al., 1997). Briefly, ELISA plates were coated with
100 ml VP1/VLP (1 mg/ml) and incubated with serial dilutions of CSF or
sera. Human IgG was captured by a biotin-conjugated anti-human Fc
antibody (eBioscience) and detected by an avidin horseradish peroxid-
ase (eBioscience). Antibody titres in CSF as well as serum were
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adjusted to the total amount of IgG in the particular compartment.
Results were expressed as arbitrary units, which were standardized
using the same human serum as standard.
HLA-A*0201/JC virus VP136 and VP1100
tetramers and tetramer staining
HLA-A*02:01 tetrameric complexes were synthesized as previously
described (Ogg et al., 1998). Briefly HLA-A*02:01, b2 microglobulin
and epitope peptide were refolded and isolated using size exclusion
chromatography. Site-specific biotinylation was achieved through add-
ition of the BirA target sequence to the last C terminal extracellular
domain of the HLA-A*0201 molecule. Tetrameric complexes were
generated using Extravidin-PE (Sigma). Phytohaemagglutinin-
expanded brain-infiltrating cells were stimulated with anti-CD2/CD3/
CD28 MACs beads (Miltenyi Biotec) and at Day 5 after stimulation,
cells were washed and resuspended to a concentration of 5  106
cells/ml; 100ml were stained with 3 ml of Phycoerythrin-coupled tetra-
meric HLA-A*02:01/JCV VP136 or HLA-A*02:01/JCV VP1100. After
30 min incubation at 37C, the cells were washed and stained with
anti-CD3 (PB, eBiolegend) and anti-CD8 (FITC, Dako) for additional
30 min on ice. Cells were then washed and fixed with 0.5% parafor-
maldehyde before analysis by flow cytometry.
Results
Two cases of natalizumab-associated
PML-IRIS
Two male patients of 41 and 43 years with relapsing–remitting
multiple sclerosis presented with clinical signs (visual field defect
in Patient 1; monoparesis in Patient 2) and imaging findings
suspicious of PML in July 2009 and January 2010, respectively
(Fig. 1A; Supplementary Figs. 1 and 2; Supplementary Tables 1
and 2) after 28 and 40 months, respectively, of natalizumab treat-
ment. Natalizumab was stopped immediately, and several rounds
of plasmapheresis performed. Both patients subsequently de-
veloped PML-IRIS with patchy or band-like areas of contrast
enhancement on MRI (Fig. 1A) and worsened clinical findings of
complete loss of vision in Patient 1, and hemiplegia, hemianopia
and neuropsychological deterioration in Patient 2. With respect to
diagnostic workup, JC virus loads in urine, serum and CSF samples
were kindly quantified by Prof. H.H. Hirsch (Transplantation
Virology, Institute for Medical Microbiology, Department of
Biomedicine, University of Basel, Switzerland) and by Dr E.O.
Major [Laboratory of Molecular Medicine and Neuroscience
(LMMN), NINDS, NIH Bethesda, USA]. Details regarding polymer-
ase chain reaction methodologies are provided in the
Supplementary Material. Patient 1 was immediately diagnosed as
PML based on a positive CSF JC virus viral load, although it was
low (Fig. 1B). Diagnosis in Patient 2 was more complicated with
repeatedly negative polymerase chain reaction results for CSF JC
virus viral load until the third positive testing, just above threshold
levels (Fig. 1B and Supplementary Fig. 3; 12 copies; threshold 10
copies in the NIH reference laboratory). In contrast to the low or
borderline JC virus CSF viral loads, antibody testing for JC virus
major capsid protein (VP1/VLP)-specific antibodies in serum and
CSF, which was established during this study, revealed strong
intrathecal antibody response with 95- to 180-fold higher VP1/
VLP-specific antibody titres in the CSF compared with serum after
adjusting total IgG concentrations to the same levels (Fig. 1C).
Hence, different from the polymerase chain reaction testing for
viral DNA, the intrathecal antibody response left no doubt of
CNS infection by JC virus at the time of PML-IRIS. The analysis
of the IgG subclasses in Patient 2 demonstrated that intrathecal
antibodies are mainly IgG1 and IgG3 (Fig. 1D). These data indicate
a strong JC virus-specific humoral immune response that is con-
fined to the CNS compartment and directed primarily against the
major structural JC virus protein VP1/VLP. Whether minor com-
ponents of the antibody response target other JC virus proteins
remains to be determined.
Due to the difficulties in diagnosing PML, Patient 2 underwent a
diagnostic brain biopsy to confirm or refute PML (Supplementary
Fig. 3). Neuropathological examination failed to show the typical
signs of PML, i.e. nuclear inclusions in hyperchromatic oligo-
dendrocytes and bizarre astrocytes, but rather a paucity of CNS
cells and massive perivascular and parenchymal lymphomononuc-
lear infiltrates (Fig. 2A), reactive gliosis with stellate astrocytes
(Fig. 2B) and predominance of diffuse and destructive parenchy-
mal infiltrates of foamy macrophages (Fig. 2C). The majority of
cells stained positive for HLA-DR, which is usually exclusively
found on activated microglia and absent in normal brain tissue
(Fig. 2D). T cells (Fig. 2E) and B cells (Fig. 2G) were present in
the infiltrate, and a high proportion of the latter stained positive
for the plasma cell marker CD138 (Fig. 2H). Part of the biopsy
tissue was processed, and CNS-derived mononuclear cells were
also characterized by flow cytometry. Cells (96.5%) expressed
the pan-haematopoietic cell marker CD45 (data not shown) and
among them 42.4% expressed the pan-T cell marker CD3 +
(Fig. 2F). Of these, 24.1% were CD8 + and 70.4% CD4 + T
cells (Fig. 2F). Almost all T cells expressed the memory marker
CD45RO (Fig. 2F). Twenty-nine per cent of CNS-infiltrating cells
expressed the B cell marker CD19 (Fig. 2I), and among these
86.1% were positive for CD27/CD38 (Fig. 2I), i.e. they were
memory B cells/plasma cells. A marker for microglia/monocytes/
macrophages was not included in the fluorescence-activated cell
sorting panel, but from the immunohistochemistry studies these
cells probably constitute another important part of immune cell
infiltrate. Accordingly, a diagnosis of inflammatory demyelinating
disease, rather than PML, was made. Subsequent immunohisto-
chemistry for JC virus was negative, but sparse nuclear signals for
JC virus DNA were found by the second attempt of in situ hy-
bridization (data not shown), which together with the low JC virus
viral load and strong intrathecal antibody response confirmed the
initial suspicion of PML and pointed towards IRIS rather than the
underlying demyelinating disease as being responsible for the
neuropathological findings.
Antigen specificity of brain-infiltrating
T cells
Next, we characterized the antigen specificity and frequency of
brain-infiltrating T cells. Brain-derived mononuclear cells were
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Figure 1 (A) MRI images at the time of suspected PML and during PML-IRIS in Patients 1 and 2. (Top) T1-weighted images after
administration of gadolinium contrast agent. Patient 1 shows minimal patchy enhancement (white arrowhead) in the left occipital
T1-hypointense area, and Patient 2 shows first a patchy, and later band-like enhancement in various locations (white arrowheads).
(Bottom) T2-weighted images with a circumscript left occipital T2-hyperintense lesion that expands between July and September 2009 in
Patient 1. In Patient 2, the parieto-occipital T2-hyperintense lesion at the time of suspected PML later extends to almost the entire right
hemisphere, (B) JC viral load in urine, serum and CSF in Patients 1 and 2. (C) ELISA of CSF and serum, obtained at the same time, against
JC virus VP1/VLP in PML-IRIS Patient 1 (left), and in PML-IRIS Patient 2 (right). (D) Analysis of the IgG subclasses in Patient 2 in CSF and
serum. aResults provided by Prof. H. Hirsch, Department of Biomedicine, Institute for Medical Microbiology, University of Basel,
Switzerland. bResults provided by Dr Eugene O. Major, Laboratory of Molecular Medicine and Neuroscience, NINDS, NIH, Bethesda, USA.
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first expanded as bulk populations by an unbiased stimulus (phyto-
haemagglutinin; Supplementary Fig. 4A). While our culture condi-
tions favoured the expansion of CD4 + over CD8 + T cells
(Supplementary Fig. 4B), the relative composition of CD4 + T
cells remained stable as demonstrated by staining with monoclonal
antibodies against T cell receptor variable chains Vb1–Vb22
(Supplementary Fig. 4C). Due to almost 3-fold excess of
memory CD4 + over CD8 + T cells at the time of brain biopsy,
we focused our attention on CD4 + cells and assessed their speci-
ficity for JC virus. For this purpose, expanded brain T cells were
tested against recombinant JC virus capsid protein VP1/VLP and
against tetanus toxin protein in proliferative assays. We directly
compared brain-derived versus CSF- or peripheral blood-derived
T cells as well as versus unmanipulated peripheral blood mononu-
clear cells. As shown in Fig. 3A, brain-derived T cells responded
with a stimulation index 4600 against VP1/VLP protein with
no response against tetanus toxoid. Stimulatory indices against
VP1/VLP and tetanus toxoid in the CSF were 7 and 14,
respectively, and in phytohaemagglutinin-expanded peripheral
blood mononuclear cells the responses to VP1/VLP and tetanus
toxoid were negative and moderately positive (stimulatory index
of 6.5), respectively. Unmanipulated peripheral blood mononu-
clear cells showed a significantly stronger response to tetanus
toxoid compared with VP1/VLP in a 7-day primary proliferation
assay.
Functional phenotype of
brain-infiltrating CD4+ T cells
We then examined if intracerebral CD4 + T cells belonged to one
of the major T helper (Th) subtypes, Th1, Th2 or Th17 cells, based
on their cytokine secretion pattern. Expanded bulk T cell popula-
tions from the brain, CSF and peripheral blood mononuclear cells,
as well as unmanipulated peripheral blood mononuclear cells, were
examined by intracellular cytokine staining against IFN-, IL-4 and
Figure 2 (A) PML-IRIS with massive perivascular and parenchymal infiltration (haematoxylin). (B) Reactive gliosis with numerous stellate
astrocytes (anti-glial fibrillary acidic protein) and (C) diffuse and destructive parenchymal infiltration of foamy macrophages (anti-CD68).
(D) The vast majority of infiltrating and resident cells express HLA-DR. (E) Perivascular and parenchymal infiltrates are rich in T cells
(anti-CD3). (F) Brain-infiltrating cells (42.4%) of CD45 + are CD3 + T cells (boxed population on left), and of these 24.1% and 70.4%,
respectively, CD8 + and CD4 + T cells, respectively (middle). In both T cell populations, almost all cells express the memory marker
CD45RO (right). (G) Perivascular and parenchymal infiltrates are also rich in B cells (anti-CD20) and (H) can further be characterized as
plasma cells (anti-CD138). (I) Flow cytometric analysis shows that 29% of CD45 + cells are B cells (anti-CD19; left), and of these 86.1%
are memory B cells/plasmablasts or plasma cells (right). The hallmarks of PML, bizarre giant astrocytes and oligodendrocytes with enlarged
hyperchromatic nuclei, were absent. Scale bar = 100mm.
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IL-17, the signature cytokines of Th1-, Th2- and Th17 cells.
IL-17-producing cells were hardly detectable (Fig. 3B), while
IFN--secreting cells made up between 46.1% and 53.2% in
cells from the brain and CSF (Fig. 3B). When combining intracel-
lular staining for IFN- and IL-4, the situation was remarkably
different. In the brain- and CSF-derived population, Th1-, Th2-
and bifunctional Th1-2 cells (secreting both IL-4 and IFN-)
were similar in frequency (Fig. 3B), while Th2 cells predominated
in the peripheral blood-derived, phytohaemagglutinin-expanded
cells (Fig. 3B). Brain-derived CD4 + T cells (32.7%) had a bifunc-
tional Th1-2 phenotype.
We then examined whether bifunctional Th1-2 CD4 + T cells
were also abundant in the brain- and CSF-derived population
from another patient with PML-IRIS and two more patients with
PML. We analysed the phenotype of brain-derived expanded bulk
T cell populations from the patient with AIDS, who developed
PML/PML-IRIS. We found that 15.7% of intracerebral CD4 +
T cells had a bifunctional Th1-2 phenotype (Fig. 4A), while
IL-17-producing cells were hardly detectable and IFN--secreting
cells made up 450% (Fig. 4A). We also analysed the phenotype
of CSF-derived expanded bulk T cell populations from two pa-
tients with PML, one with hyper-IgE syndrome and the other
with idiopathic CD4 lymphocytopenia. CSF expanded CD4 + T
cells (26.9%) in the patient with PML/hyper-IgE syndrome and
14.4% in the patient with PML/idiopathic CD4 lymphocytopenia
had a bifunctional Th1-2 phenotype. These percentages were
higher than those observed in control patients not suffering
from PML. We analysed the phenotype of CSF-derived, expanded
bulk T cell populations from two control patients, one with neuro-
syphilis and the other with relapsing–remitting multiple sclerosis. In
both patients, the percentage of CD4 + T cells with a bifunctional
Th1-2 phenotype was 4% (Fig. 4B).
Fine specificity and frequency of
brain-infiltrating T cells
To determine which specific JC virus peptides are recognized by
brain-infiltrating T cells, 204 15-mer peptides spanning all JC virus
proteins (Agno, VP1, VP2, VP3, large-T and small-T) were synthe-
sized and arranged in a set of 82 pools, where each peptide
Figure 3 (A) Phytohaemagglutinin-expanded bulk mononuclear cell populations from the brain biopsy (left), CSF (second from left) and
peripheral blood mononuclear cells (PBMCs) (third from left) as well as unmanipulated peripheral blood mononuclear cells (right) were
tested against JC virus VP1/VLP protein and tetanus toxoid protein (TTx). Results show the mean stimulatory index  SEM. Note the
different scales for the y-axis. (B) Ex vivo quantification of Th1-, Th2-, Th17- and Th1-2 cells in phytohaemagglutinin-expanded CD4 + T
cells from brain biopsy (left), CSF (second from left), peripheral blood mononuclear cellss (third from left) and in unmanipulated peripheral
blood mononuclear cells (right). Numbers represent the percentage of positive cells. Th1 were identified as CD4 + IFN- + IL-17A/IL-4;
Th17 cells as CD4 + IL-17A + IFN-; Th2 as CD4 + IL-4 + IFN-; and Th1-2 as CD4 + IFN- + IL-4 + . PHA = phytohaemagglutinin.
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appeared twice, but in two different pools (Supplementary Table
4). Brain-derived T cells responded to multiple pools (Fig. 5A;
pools 1–41, and Supplementary Fig. 5A; all 82 pools). We identi-
fied 15 immunogenic candidate peptides (Supplementary Fig. 5B)
that were then tested individually (Supplementary Fig. 5C) and led
to the identification of 11 stimulatory peptides (peptides with
stimulatory index 410) (Fig. 5B). The response was directed
against peptides 4 (Agno25, the number denotes the first amino
acid of the 15-mer peptide; peptides with stimulatory index 425
in bold), 20 (VP134), 23 (VP154), 27–29 (VP174) (all VP174 pep-
tides; 28 and 29 are variants of peptide 27 with single amino acid
mutations), 72 (VP1310), 73 (VP1319), 76 (VP1335), 191 (LTAg668)
and 195 (sTAg82). Thus, brain-derived T cells responded to several
JC virus proteins (Agno, VP1, LTAg, sTAg), however, by far the
strongest against VP1 (six peptides). That VP1 is the prime target
is supported by an even stronger response against entire VP1/VLP
protein (Fig. 3A) and by the higher precursor frequencies of
VP1-specific T cells (between 1/294 and 1/714 T cells responding
to peptides VP134, VP1319 and VP174) when compared with cells
responding to Agno25 (1/14492) and LTAg668 (1/1449) (Fig. 5C).
When we examined phytohaemagglutinin-expanded CSF- and
peripheral blood-derived T cells, CSF cells showed only weak
responses against Pool 39 and peptide LTAg668 contained in this
pool, and peripheral blood mononuclear cells were negative
(Supplementary Fig. 6A and B). Remarkably, peptide VP134, the
peptide that elicits the strongest response with respect to stimu-
latory index (Fig. 5B) and precursor frequency (Fig. 5C), contains
the JC virus epitope VP136, one of the two epitopes together with
VP1100 that are recognized by HLA-class I-restricted CD8
+ T cells
in the context of HLA-A*02:01 (Du Pasquier et al., 2003). Patient
2 with PML-IRIS was HLA-A*02:01 + (HLA-class I and -class II
types in ‘Material and methods’ section). We determined the
frequency of CD8 + T cells specific of these two HLA-A*02:01
JC virus epitopes in the phytohaemagglutinin-expanded
brain-infiltrating CD8 + T cells by tetramer staining.
Phytohaemagglutinin-expanded brain-infiltrating CD8 + T cells
(0.8%) were specific for VP136 and 0.6% for VP1100 (Fig. 5D).
With respect to HLA-class II, Patient 2 expressed the multiple
sclerosis-associated HLA-DR haplotype DRB1*15:01 and
DRB5*01:01. The JC virus-specific CD4 + T cell response was
largely restricted by DRB1*15:01/B5*01:01, when VP1/VLP pro-
tein was presented by APCs from a DRB1*15:01/B5*01:01 homo-
zygous donor (data not shown). These data demonstrate that,
similar to intrathecal antibodies, the CD4 + T cell response is
Figure 4 (A) Ex vivo quantification of Th1-, Th2-, Th17- and Th1-2 cells in brain-derived expanded bulk T cell populations from the
patient with AIDS, who developed PML/PML-IRIS. (B) Ex vivo quantification of Th1-, Th2- and Th1-2 cells in CSF-derived expanded bulk
T cell populations from two patients with PML, one with hyper-IgE syndrome (first upper) and the other with idiopathic CD4 lympho-
cytopenia (second upper), and from two control patients, one with neurosyphilis (first lower) and the other with relapsing–remitting
multiple sclerosis (second lower). Numbers represent the percentage of positive cells. Th1 were identified as CD4 + IFN- + IL-4;
Th2 as CD4 + IL-4 + IFN-; and Th1-2 as CD4 + IFN- + IL-4 + . PHA = phytohaemagglutinin.
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mainly directed against the major structural JC virus protein VP1
and that peptide VP134 contains an epitope for both virus-specific
CD4 + and CD8 + T cells. Such a focus of CD4 + and CD8 + T cells
on the same immunodominant epitope has previously been shown
for an influenza nucleoprotein peptide (Carreno et al., 1992).
Since PML is characterized by oligodendrocyte lysis and release
of myelin and since the patient suffers from multiple sclerosis, it
was of interest to examine if brain-derived T cells responded to
myelin proteins. Phytohaemagglutinin-expanded brain-derived T
cells were tested against overlapping peptides spanning the
major myelin proteins, myelin basic protein, proteolipid protein
and myelin oligodendrocyte glycoprotein, but none of the
myelin peptides was recognized despite a strong response against
JC virus VP1/VLP protein (Supplementary Fig. 7).
Fine specificity and functional
phenotype of JC virus-specific CD4+
T cell clones
Previous data have shown that CD4 + differentiate into certain T
helper phenotypes such as Th1 cells (IFN- producers), Th17 cells
secreting IL-17, Th2 cells expressing the signature cytokine IL-4 or
T regulatory cells based on the expression of certain transcription
factors (Zhu et al., 2010). The differentiation into Th1 or Th2 cells
is considered mutually exclusive and controlled by the transcription
factors T-bet (Th1) and Gata-3 (Th2) (Zhu et al., 2010). Based on
these data, our finding of committed memory cells with a bifunc-
tional (Th1-2) phenotype was highly unexpected, and we there-
fore established VP1/VLP-specific T cell clones to examine this
point at the clonal level. VP1/VLP-specific T cell clones were gen-
erated as described above. Initially 21 VP1/VLP-specific single
cell-derived cultures were generated by limiting dilution and char-
acterized for T cell receptor V beta expression, functional pheno-
type and fine specificity (Table 1). This characterization allowed
the identification of 11 presumed different T cell clones. The
number of single cell growing cultures corresponding to each
T cell clone gives an indication of the frequency of each T cell
clones in the brain infiltrate (Fig. 6A). T cell clone-4 was most
abundant and represented by five colonies emerging from single
growing wells, followed by T cell clone-2 with three single cell
growing cultures, T cell clones-1, -8, -9 and -10 with two single
cell growing cultures and finally T cell clone-3, -5, -6, -7 and -11
with only one single cell growing culture. The fine specificity of
Figure 5 (A) Proliferative response of brain-derived phytohaemagglutinin-expanded cells against 204 overlapping 15-mer peptides
spanning all open reading frames of JC virus (covering Agno, VP1, VP2, VP3, large-T and small-T proteins) and organized in 41 pools of
five peptides each. Results show the mean stimulatory index  SEM. The different colours of the bars correspond to the different open
reading frames. Schematic representation of the five open reading frames in the JC virus genome (top right). (B) Proliferative response of
brain-derived bulk mononuclear cell populations against individual JC virus peptides. Results show the mean stimulatory index  SEM.
Note the different scales of the y-axes (A) and (B). (C) Precursor frequency of T cells specific of the five JC virus peptides inducing the
strongest proliferative responses in phytohaemagglutinin-expanded cells from brain biopsy. (D) Percentage of CD8 + T cells that bind
HLA-A*02:01-VP136 tetramers (middle) and HLA-A*02:01-VP1100 tetramers (lower). SI = stimulatory index.
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the 11 T cell clones is summarized in Fig. 6B. Each T cell clone was
tested against 64 15-mer peptides spanning VP1 protein and led
to the identification of the following stimulatory peptides: VP134
(recognized by T cell clone-1 and -2), VP154 (recognized by T cell
clone-3), VP174 (all VP174 peptides, recognized by T cell clone-4),
VP191 (recognized by T cell clone-5), VP1143 (recognized by T cell
clone-6), VP1229 (recognized by T cell clone-7), VP1319 (recog-
nized by T cell clone-8 and -9) and VP1335 (recognized by T cell
clone-10 and -11). Taking into account both the number of dif-
ferent T cell clones recognizing a specific peptide and the fre-
quency of each T cell clone in the brain infiltrate, the
immunodominant peptides recognized by VP1 specific brain infil-
trating T cell clones were VP134, VP174, VP1319 and VP1335 con-
firming the fine specificity obtained using the brain-derived bulk
cell population (Fig. 6C). Intracellular cytokine staining of these T
cell clones revealed Th1-2 and Th1 phenotypes (Fig. 7A). Five T
cell clones representing the 57% of the brain-derived VP1-specific
single cell growing cultures showed a Th1-2-, and six T cell clones
representing the 43% of the brain-derived VP1-specific single cell
growing cultures, a Th1 phenotype (Fig. 7B). Specificity and func-
tional phenotype did not correlate. For three of the immunodomi-
nant peptides (VP134, VP1319 and VP1335), we found T cell clones
with both phenotypes. The T helper phenotype of Th1-2 and Th1
T cell clones was confirmed by measuring IL-4 and IFN- protein
secretion by ELISA and by determining the expression of messen-
ger RNAs of the transcription factors Gata3 and T-bet. Th1-2
T cell clones (n = 5) secreted IL-4 in addition to IFN-, while
IL-4 secretion was barely detectable in Th1 T cell clones (n = 6)
(Fig. 7C). Cytokine secretion profiles were not due to stimulation
with phytohaemagglutinin, since the same stable patterns were
observed after specific stimulation with VP1/VLP protein by
intracellular cytokine staining or ELISA measurements from culture
supernatants (Supplementary Fig. 8A and B). Transcription factor
expression confirmed the phenotype of the T cell clones. Th1-2
T cell clones (n = 5) expressed messenger RNA for Gata3 and
T-bet, while Th1 T cell clones (n = 6) only expressed T-bet
(Fig. 7D).
Discussion
The viral aetiology of PML was shown almost 40 years ago, but
still relatively little is known about the immune mechanisms that
control JC virus infection. CD8 + JC virus-specific cytotoxic T cells
have been related to recovery from PML (Koralnik et al., 2002; Du
Pasquier et al., 2004a), and two viral epitopes have been identi-
fied in HLA-A*02:01-positive individuals (Du Pasquier et al.,
2004a, b). In contrast, limited information is available on the
fine specificity and characteristics of JC virus-specific CD4 + T
cells in PML and even less in PML-IRIS (Jilek et al., 2010). The
virus-specific T cell response at the site of infection, i.e. the CNS
parenchyma, has not been examined at all.
Despite the limitation to a few patients and the bulk of the
information deriving from Patient 2, our data provide novel in-
sights into this subject and lead us to propose the following patho-
genetic events during PML-IRIS under natalizumab treatment. The
anti-VLA-4 antibody inhibits immune surveillance of JC virus in-
fection at immunoprivileged sites, such as the brain, by blocking
cell migration (Stuve et al., 2006) and local antigen presentation in
the CNS (Del Pilar Martin et al., 2008). As a result, pathological
neurotropic JC virus variants may lead to PML in a small number
(1/500–1/1000) of treated patients with multiple sclerosis for rea-
sons that are not yet understood (Ransohoff, 2005; Major, 2010).
As soon as PML is suspected and natalizumab is stopped or ac-
tively removed by plasmapheresis, fully functional and activated
T cells regain access to the CNS compartment, initiate the strong
inflammation that is typical for PML-IRIS and effectively eliminate
virus-infected cells by a number of mechanisms including CD4 +
and CD8 + T cells and antibody-forming plasma cells.
Among the CNS-infiltrating T- and B cells, CD4 + T cells with
either Th1- or the above bifunctional Th1-2 phenotype are prob-
ably the most critical element based on the following findings.
Their parallel secretion of Th1- (IFN-) and Th2 (IL-4) cytokines
probably explains the expression of HLA-class II molecules on resi-
dent cells such as virus-infected astrocytes and microglia, but also
on infiltrating immune cells (Fig. 2D), since IFN- is the strongest
inducer of HLA-class II. Although colocalization studies of HLA-DR
with an astrocytic marker such as glial fibrillary acidic protein could
not be performed due the paucity of material, the widespread
expression of HLA-DR (Fig. 2D) strongly suggests that these are
also positive. In analogy to multiple sclerosis and its animal model
experimental autoimmune encephalitis, where local reactivation of
immigrating T cells has been demonstrated (Flugel et al., 2001),
we assume that JC virus-specific Th1-2 and also Th1 cells are
probably locally reactivated by recognition of JC virus peptides
on JC virus-infected, HLA-class II positive astrocytes, microglia/
macrophages or recruited dendritic cells. Furthermore, the secre-
tion of large quantities of IL-4 leads to activation and expansion of
Table I Characterization of VP1 specific brain-infiltrating
TCC
TCC # Well # Th phenotype TCR Vb Fine specificity
TCC-1 17A Th1-2 Vb2 VP134
18A Th1-2 Vb2 VP134
TCC-2 16A Th1 Vb2 VP134
28A Th1 Vb2 VP134
18B Th1 Vb2 VP134
TCC-3 29A Th1 Vb18 VP154
TCC-4 10A Th1-2 Vb5.1 VP174-1, VP174-2, VP174-3
14A Th1-2 Vb5.1 VP174-1, VP174-2, VP174-3
27A Th1-2 Vb5.1 VP174-1, VP174-2, VP174-3
30A Th1-2 Vb5.1 VP174-1, VP174-2, VP174-3
19B Th1-2 Vb5.1 VP174-1, VP174-2, VP174-3
TCC-5 3A Th1 Vb - VP191
TCC-6 11B Th1 Vb - VP1143
TCC-7 12B Th1-2 Vb2 VP1229
TCC-8 21A Th1-2 Vb - VP1319
25A Th1-2 Vb - VP1319
TCC-9 36A Th1 Vb - VP1319
1B Th1 Vb- VP1319
TCC-10 19A Th1-2 Vb5.3 VP1335
3B Th1-2 Vb5.3 VP1335
TCC-11 24A Th1 Vb - VP1335
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memory B cells/plasmablasts in the CNS compartment (Fig. 2G–I)
with the consequence of virus-specific antibody secretion. Locally
produced JC virus capsid protein (VP1)-specific IgG antibodies may
recognize virus-infected oligodendrocytes, which could then be
lysed by complement- or antibody-mediated cellular cytotoxicity.
The relative increase in the CSF of IgG1 and IgG3 antibodies,
which bind complement with high affinity and have been
described in the context of other viral infections (Cavacini et al.,
2003), supports this notion. The exact sequence of events,
whether the functional priming of Th1 and Th1-2 cells occurs in
the periphery or the CNS and whether IFN- and IL-4 jointly con-
tribute to the strong IgG1 and IgG3 antibody secretion, cannot be
proven by our data. However, the observation in patients with
HIV with PML that higher JC virus-specific IgG production and
JC virus-specific T cell responses at diagnosis were associated
with better survival (Khanna et al., 2009) supports the above rea-
soning. Since infected oligodendrocytes do not express HLA-class
II, but effectively express HLA-class I, it can be expected that JC
virus-specific, HLA-A2-restricted CD8 + cytolytic T cells (Koralnik
et al., 2001, 2002) also contribute by killing JC virus-infected
oligodendrocytes and/or astrocytes. That these previously
described cells in the peripheral blood of patients with AIDS
with PML are probably also participating in the local eradication
of JC virus in the brain is supported by our observation of CD8 +
Figure 6 (A) Doughnut representing the frequency of each individual T cell clone in the brain biopsy. (B) Proliferative response of T cell
clones against 64 individual VP1 peptides. Results show the mean stimulatory index  SEM. (C) Schematic representation of the
immunodominant peptides identified for the brain-derived bulk population (upper, show the mean stimulatory index  SEM) and for the
different T cell clones (lower graph; the different colours correspond to the different T cell clones and each single cell growing culture is
represented by a square).
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T cells specific for JC virus VP136 and JC virus VP100 as defined by
peptide-loaded HLA-A*02:01 tetramers. Infected astrocytes may
not only serve as local antigen presenting cells for CD4 +
virus-specific T cells, but may also be killed by Th1-2 cytolytic
cells (Hemmer et al., 1997), but this together with the question
of DR expression by astrocytes will require further examination.
The above pathogenetic scenario accounts for the effects of
IFN-- and IL-4, i.e. the widespread expression of HLA-class II
molecules in the brain as well as the strong intrathecal antibody
response against JC virus, however, it is still puzzling that a large
fraction of brain-infiltrating cells show a Th1-2 phenotype.
Previously, these cells were referred to as Th0 cells and considered
an intermediate differentiation step before naive cells develop into
memory cells committed to either Th1 or Th2 lineage (Mosmann
and Coffman, 1989). This notion has, however, already been con-
tended early based on following the cytokine patterns of single
clones (Kelso, 1995). Today, Th1- and Th2 cells are understood to
have mutually exclusive fates (Ansel et al., 2006). However, indi-
vidual T cell clones with dual cytokine secretion have been
described as Th0 cells in measles virus infection (Howe et al.,
2005) and among disease-exacerbating autoreactive T cells
during altered peptide ligand-based therapy of multiple sclerosis
(Bielekova et al., 2000). Our present observation of stable Th1-2
clones based on intracellular cytokine staining, cytokine secretion
and transcription factor expression point to a defined T helper cell
subpopulation in the CNS rather than an intermediate or transient
differentiation stage. Due to the abovementioned ill-defined role
of Th0 cells and the prior controversy about their existence as
terminally differentiated cells, we propose here to refer to
IFN-/IL-4 T helper cells as bifunctional Th1-2 cells. The context
and signals that lead to this Th1-2 differentiation need further
examination. In a recently published study in a viral infection
model, the authors demonstrated that non-protective Th2 cells
could be converted to stable IFN-/IL-4-expressing and protective
CD4 + cells by concerted action of antigen-specific T cell receptor
signal, type I and –II interferons and IL-12 (Hegazy et al., 2010;
Zhu and Paul, 2010). To our knowledge, our present report is the
first evidence for the existence of a stable GATA-3 +T-bet + and
IL-4 + IFN- + Th1-2 phenotype in vivo in humans. It is conceivable
that these cells were reprogrammed in the brain, and they could
well explain the unusually strong immune response and fulminant
course of PML-IRIS. The putative protective role of Th1-2 bifunc-
tional CD4 + T cells in JC virus infection and where their differen-
tiation occurs requires further investigation.
Regarding the fine specificity of brain-infiltrating T cells our data
are interesting in several aspects. The JC virus-specific T cell re-
sponse is overall broad since peptides from almost all JC virus
proteins are recognized, which is consistent with our efforts to
Figure 7 (A) Representative flow cytometry analyisis of intracellular IFN- and IL-4 production by a Th1-2 (top) and a Th1 (bottom)
VP1/VLP-specific CD4 + T cell clone. (B) The dot plot represents the percentage of VP1-specific, brain-derived single cell cultures with
Th1-2 and Th1 phenotype by intracellular cytokine staining. Each dot corresponds to one of the 21 single cell cultures analysed. The
doughnut represents the functional phenotype of each T cell clone (TCC). (C) ELISA detection of IFN- and IL-4 production in culture
supernatants of Th1-2 T cell clones (n = 5, black bars) and Th1 T cell clones (n = 6, white bars) 72 h after stimulation with phytohaem-
agglutinin. Results show the mean  SEM. (D) Real-time polymerase chain reaction analysis for transcription factors Gata3 and T-bet of
Th1-2 T cell clones (n = 5, black bars) and Th1 T cell clones (n = 6, white bars). Values are relative expression compared with brain-derived
phytohaemagglutinin-expanded cells (calibrator = 1). Results show the mean  SEM.
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map immunodominant epitopes of JC virus for peripheral blood-
derived CD4 + T cells in healthy donors and patients with multiple
sclerosis (Aly et al., in preparation). However, 450% of peptides
recognized by brain-derived CD4 + T cells are part of the major
structural protein VP1. Furthermore, VP1-specific T cells dominate
with respect to strength of proliferation and precursor frequency.
It is intriguing that VP134-48 contains not only a major epitope for
cytotoxic, HLA-A*02:01-restricted CD8 + T cells (Du Pasquier
et al., 2003), which we found in the brain of the patient with
PML-IRIS by tetramer staining, but also for HLA-DRB1*15:01/
DRB5*01:01-restricted CD4 + T cells. Furthermore, the recognition
of peptide VP174 and two variants thereof with single amino acid
substitutions indicates that recognition of this epitope may be rele-
vant to protect the host from immune evasion during persistent JC
virus infection. This has been shown previously for human im-
munodeficiency (Borrow et al., 1997) and lymphocytic choriome-
ningitis virus infections (Ciurea et al., 2001). The vigorous
intrathecal antibody response against VP1 further underscores
the role of this structural protein. Therefore, we speculate that
VP1 is important for protective immune responses against JC
virus-infected brain cells and that these are mediated by antibo-
dies, CD4 + and CD8 + T cells. The strength of this response is
probably in part determined by the HLA type of Patient 2, who
expresses both the major multiple sclerosis risk allele DRB1*15:01/
DRB5*01:01 and A*02:01, which present an identical VP1 epitope
to CD4 + and CD8 + T cells. He may therefore have experienced a
particularly pronounced T cell-mediated immune response in the
brain with its immunopathological consequences of massive
PML-IRIS, brain swelling (Fig. 1A, Supplementary Fig. 2C), and
neurological worsening. As already pointed out by others
(Cinque et al., 2003) the JC virus-specific immune response is a
double-edged sword. Without a functional immune response brain
cells are lysed by uncombated viral infection. On the other hand, if
unleashed, the vigorous JC virus-specific response during PML-IRIS
causes brain inflammation and oedema, and while it effectively
eliminates JC virus from the CNS, it may lead to death of the
patient if not at least temporarily attenuated by immunosuppres-
sion (Tan et al., 2009b).
The cellular and humoral JC virus-specific immune response in
the brain during PML-IRIS not only complicates the treatment, but
may also cloud the diagnosis of PML in the first place. Different
from current routine, which relies on CSF JC virus viral load and, if
a biopsy is performed, on immunohistochemistry and in situ hy-
bridization for JC virus antigen and DNA, respectively, the intra-
thecal antibody response against VP1 appears more robust and
should be examined. In both patients with PML-IRIS in this
study, intrathecal VP1-specific antibody titres were extremely
high despite almost undetectable JC virus DNA by polymerase
chain reaction and in situ hybridization. The important role of
JC virus antibody testing is supported by prior observations of
high antibody titres in patients with AIDS with PML (Weber
et al., 1997), but also by recent data in natalizumab-treated pa-
tients with multiple sclerosis (Gorelik et al., 2010).
Another important and unexpected observation of this study is
that, unlike the JC virus-specific antibody response, pathogeneti-
cally relevant T cells are confined to the CNS parenchyma itself,
and the CSF is of little use for investigating T cell specificity and
function. This finding is probably highly relevant not only to
PML-IRIS, but also to multiple sclerosis, where most studies
have focused on CSF as a surrogate for the responses within the
CNS from obvious reasons, i.e. because CNS tissue is rarely avail-
able to investigators. Future research should therefore make every
possible effort to examine biopsy or autopsy tissue if it can be
acquired. When studying the brain-infiltrating CD4 + T cells of
this patient with multiple sclerosis with PML-IRIS, we were further
surprised to see that none of the peptides from three major myelin
proteins were recognized, suggesting that bystander activation or
recruitment of myelin-specific T cells during massive brain inflam-
mation does not occur or is a minor part of the inflammatory
response, while the majority of cells are exquisitely specific for
the causal agent.
Based on our data in natalizumab-related PML-IRIS we suggest
that immunomodulatory therapies that attenuate the vigorous
T cell response should be implemented as soon as PML-IRIS is
diagnosed. Unfortunately, there is no treatment that is supported
by sufficient clinical testing. However, the use of drugs that inhibit
viral replication such as mefloquine (Brickelmaier et al., 2009), but
also type I interferons (O’Hara and Atwood, 2008) appears rea-
sonable. While experience from a phase III trial, in which patients
with multiple sclerosis received the combination of IFN-b and
natalizumab, raised the suspicion that it may increase the risk
for PML (Kleinschmidt-DeMasters and Tyler, 2005), transient
interferon-b therapy could be useful in the case of
natalizumab-associated PML-IRIS. It is well tolerated, probably
has antiviral properties against JC virus (O’Hara and Atwood,
2008), blocks blood-brain barrier opening via inhibition of matrix
metalloproteases (Waubant et al., 2003) and shedding of adhesion
molecules (Calabresi et al., 1997), and has protective effects in
the CNS during autoimmune encephalitis (Prinz et al., 2008).
This suggestion needs clinical testing, and further therapies
should also be assessed.
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